Confident Bayer Diagnostics could notch up +6% this year
This article was originally published in Clinica
Executive Summary
Bayer's healthcare division may have had a rocky year on three fronts - given its voluntary withdrawal of cholesterol-lowering drug Lipobay/Baycol, production and supply difficulties relating to the recombinant factor VIII vaccine Kogenate and the poor economic conditions - but its diagnostics division is bucking the depressed trend.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.